Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2023 Jul 14

PMID 37446806

Authors

Manman Xu

Xinpu Han

Hongtai Xiong

Yijie Gao

Bowen Xu

Guanghui Zhu

Jie Li

Affiliations

Soon will be listed here.

Abstract

Cancer continues to pose a severe threat to global health, making pursuing effective treatments more critical than ever. Traditional therapies, although pivotal in managing cancer, encounter considerable challenges, including drug resistance, poor drug solubility, and difficulties targeting tumors, specifically limiting their overall efficacy. Nanomedicine's application in cancer therapy signals a new epoch, distinguished by the improvement of the specificity, efficacy, and tolerability of cancer treatments. This review explores the mechanisms and advantages of nanoparticle-mediated drug delivery, highlighting passive and active targeting strategies. Furthermore, it explores the transformative potential of nanomedicine in tumor therapeutics, delving into its applications across various treatment modalities, including surgery, chemotherapy, immunotherapy, radiotherapy, photodynamic and photothermal therapy, gene therapy, as well as tumor diagnosis and imaging. Meanwhile, the outlook of nanomedicine in tumor therapeutics is discussed, emphasizing the need for addressing toxicity concerns, improving drug delivery strategies, enhancing carrier stability and controlled release, simplifying nano-design, and exploring novel manufacturing technologies. Overall, integrating nanomedicine in cancer treatment holds immense potential for revolutionizing cancer therapeutics and improving patient outcomes.

Citing Articles

Recent advances in the bench-to-bedside translation of cancer nanomedicines.

Liu Y, Zhang Y, Li H, Hu T Acta Pharm Sin B. 2025; 15(1):97-122.

PMID: 40041906 PMC: 11873642. DOI: 10.1016/j.apsb.2024.12.007.

Nanocarrier-mediated cancer therapy with cisplatin: .

Ranasinghe R, Mathai M, Alshawsh M, Zulli A Heliyon. 2025; 10(7):e28171.

PMID: 39839154 PMC: 11747978. DOI: 10.1016/j.heliyon.2024.e28171.

Monascus red pigment influence on hydroxyapatite nanoparticles-mediated renal toxicity in rats.

Alqurashy N, Yousef M, Hussein A, Kamel M, El Wakil A Sci Rep. 2025; 15(1):2715.

PMID: 39837868 PMC: 11750980. DOI: 10.1038/s41598-024-84959-z.

Advances in Preventive and Therapeutic Strategies for Oral Cancer: A Short Review.

Ma L, Kim M J Cancer Prev. 2025; 29(4):113-119.

PMID: 39790224 PMC: 11706729. DOI: 10.15430/JCP.24.027.

Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management - a comprehensive review.

Kumar N, Mangla M Cancer Chemother Pharmacol. 2025; 95(1):18.

PMID: 39754614 DOI: 10.1007/s00280-024-04747-4.

References

Dizaj S, Jafari S, Khosroushahi A . A sight on the current nanoparticle-based gene delivery vectors. Nanoscale Res Lett. 2014; 9(1):252. PMC: 4046008. DOI: 10.1186/1556-276X-9-252. View

Marianecci C, Di Marzio L, Del Favero E, Cantu L, Brocca P, Rondelli V . Niosomes as Drug Nanovectors: Multiscale pH-Dependent Structural Response. Langmuir. 2016; 32(5):1241-9. DOI: 10.1021/acs.langmuir.5b04111. View

Pourhassan H, Clergeaud G, Hansen A, Ostrem R, Fliedner F, Melander F . Revisiting the use of sPLA-sensitive liposomes in cancer therapy. J Control Release. 2017; 261:163-173. DOI: 10.1016/j.jconrel.2017.06.024. View

Akhter S, Ahmad I, Ahmad M, Ramazani F, Singh A, Rahman Z . Nanomedicines as cancer therapeutics: current status. Curr Cancer Drug Targets. 2013; 13(4):362-78. DOI: 10.2174/1568009611313040002. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Ngamcherdtrakul W, Bejan D, Cruz-Munoz W, Reda M, Zaidan H, Siriwon N . Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis. Small. 2022; 18(11):e2107550. PMC: 8959011. DOI: 10.1002/smll.202107550. View

Hile E, Fitzgerald G, Studenski S . Persistent mobility disability after neurotoxic chemotherapy. Phys Ther. 2010; 90(11):1649-57. PMC: 2967709. DOI: 10.2522/ptj.20090405. View

Ali M, Wu Y, Han T, Zang X, Xiao H, Tang Y . Simultaneous Time-Dependent Surface-Enhanced Raman Spectroscopy, Metabolomics, and Proteomics Reveal Cancer Cell Death Mechanisms Associated with Gold Nanorod Photothermal Therapy. J Am Chem Soc. 2016; 138(47):15434-15442. DOI: 10.1021/jacs.6b08787. View

Alexis F, Rhee J, Richie J, Radovic-Moreno A, Langer R, Farokhzad O . New frontiers in nanotechnology for cancer treatment. Urol Oncol. 2008; 26(1):74-85. DOI: 10.1016/j.urolonc.2007.03.017. View

10.

Li J, Dirisala A, Ge Z, Wang Y, Yin W, Ke W . Therapeutic Vesicular Nanoreactors with Tumor-Specific Activation and Self-Destruction for Synergistic Tumor Ablation. Angew Chem Int Ed Engl. 2017; 56(45):14025-14030. DOI: 10.1002/anie.201706964. View

11.

Pakunlu R, Wang Y, Saad M, Khandare J, Starovoytov V, Minko T . In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release. 2006; 114(2):153-62. DOI: 10.1016/j.jconrel.2006.06.010. View

12.

Arranja A, Pathak V, Lammers T, Shi Y . Tumor-targeted nanomedicines for cancer theranostics. Pharmacol Res. 2016; 115:87-95. PMC: 5412956. DOI: 10.1016/j.phrs.2016.11.014. View

13.

Wang X, Zhang W . The Janus of Protein Corona on nanoparticles for tumor targeting, immunotherapy and diagnosis. J Control Release. 2022; 345:832-850. DOI: 10.1016/j.jconrel.2022.03.056. View

14.

Zhao T, Huang G, Li Y, Yang S, Ramezani S, Lin Z . A Transistor-like pH Nanoprobe for Tumour Detection and Image-guided Surgery. Nat Biomed Eng. 2017; 1. PMC: 5617128. DOI: 10.1038/s41551-016-0006. View

15.

Zhang M, Hagan 4th C, Foley H, Tian X, Yang F, Au K . Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models. Acta Biomater. 2021; 124:327-335. PMC: 9083847. DOI: 10.1016/j.actbio.2021.02.001. View

16.

Talelli M, Barz M, Rijcken C, Kiessling F, Hennink W, Lammers T . Core-Crosslinked Polymeric Micelles: Principles, Preparation, Biomedical Applications and Clinical Translation. Nano Today. 2015; 10(1):93-117. PMC: 4398985. DOI: 10.1016/j.nantod.2015.01.005. View

17.

Gavas S, Quazi S, Karpinski T . Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021; 16(1):173. PMC: 8645667. DOI: 10.1186/s11671-021-03628-6. View

18.

Fiandra L, Mazzucchelli S, De Palma C, Colombo M, Allevi R, Sommaruga S . Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands. ACS Nano. 2013; 7(7):6092-102. DOI: 10.1021/nn4018922. View

19.

Zhang L, Zhang B, Liang R, Ran H, Zhu D, Ren J . A Dual-Biomineralized Yeast Micro-/Nanorobot with Self-Driving Penetration for Gastritis Therapy and Motility Recovery. ACS Nano. 2023; 17(7):6410-6422. DOI: 10.1021/acsnano.2c11258. View

20.

Torchilin V . Liposomes as delivery agents for medical imaging. Mol Med Today. 1996; 2(6):242-9. DOI: 10.1016/1357-4310(96)88805-8. View